Skip to main content
 

Rachel Haurwitz, Ph.D.

President and Chief Executive Officer

Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Natalie Sacks, M.D.

Natalie Sacks, M.D., is Chief Medical Officer at Harpoon Therapeutics (NASDAQ: HARP). Prior to joining Harpoon, Dr. Sacks was the Chief Medical Officer at Aduro Biotech and before that role, she served as an advisor on development strategy for multiple firms. Previously, she was Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen) where she played a key role in the development and approval of Kyprolis®, an FDA-approved therapy for the treatment of multiple myeloma, and in business development strategy. Prior to that, she served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, with responsibilities ranging from IND filings to late-stage development, including late-stage development of Cometriq™, an FDA-approved therapy for the treatment of medullary thyroid cancer. Earlier in her career, Dr. Sacks served as Vice President of Clinical Development at Cell Genesys, a company focused on the development of cancer vaccines and engineered chimeric antigen receptor (CAR) T cells. She serves as a Board Member for Zymeworks, Inc. (NYSE:ZYME). Dr. Sacks held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health, and her B.A. in Mathematics from Bryn Mawr College.

Robert Weisskoff, Ph.D., M.B.A.

Robert, a partner at F-Prime Capital, has worked extensively in academia and industry for more than 25 years. Prior to F-Prime Capital, he held various senior roles in pharmaceutical and medical device companies and had been a professor at Harvard Medical School, where he worked at the intersection of basic research, medical technology development and clinical research in a variety of areas. He is the author of over 100 peer-reviewed scientific papers and an inventor on six U.S. patents. Robert has served on the boards of Accuri Cytometers (acquired by Becton Dickenson), Amphora Medical, Bioconnect Systems, Ikano Therapeutics (acquired by Upsher-Smith), Laurus Labs, Tetraphase (NASDAQ:TTP), Topaz, Trivitron Healthcare, Transave (NASDAQ:INSM), ViewRay, Xcyton Diagnostics and FORUM Pharmaceuticals. He holds physics degrees from MIT and Harvard, and an M.B.A. from Columbia.

Philip Austin

Philip is a founding partner at Anterra Capital, a leading specialist investment fund in the food & agricultural sector.  He currently heads up Anterra’s US office, dedicating most of his investment efforts to furthering life science companies in the food sector.  Prior to co-founding Anterra, Philip worked in the principal investment team of Rabobank International (Amsterdam, Netherlands), supporting this global leader in agricultural banking to make investments in  groundbreaking, early stage technology companies.  Philip started his investment career with Atlas Venture in London, United Kingdom. Prior to this, he was a strategy consultant with McKinsey & Company's London and Washington, D.C. offices.  Philip holds a dual degree in Pharmaceutical Chemistry and Chemical Engineering.